ALK-Abello A/S

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: DK0061802139
DKK
227.80
-31.7 (-12.22%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About ALK-Abello A/S stock-summary
stock-summary
ALK-Abello A/S
Pharmaceuticals & Biotechnology
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
Company Coordinates stock-summary
Company Details
Boege Alle 1 , HOERSHOLM None : 2970
stock-summary
Tel: 45 45 74757645 45 747527
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Anders Hedegaard
Chairman of the Board
Ms. Lene Skole-Soerensen
Vice Chairman of the Board
Ms. Katja Barnkob
Director, Employee Representative
Ms. Nanna Carlson
Director, Employee Representative
Mr. Lars Holmqvist
Director
Mr. Jakob Riis
Director
Mr. Johan Smedsrud
Director, Employee Representative
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,527 Million
(Quarterly Results - Jun 2025)
Net Profit:
263 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

DKK 46,996 Million ()

stock-summary
P/E

42.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.06

stock-summary
Return on Equity

17.84%

stock-summary
Price to Book

7.61